
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is a clinical-stage biopharmaceutical company specializing in neurodegenerative diseases, utilizing proprietary technology platforms to develop innovative small molecules, antibodies, and vaccines. The promising early results from the PD active immunotherapy ACI-7104.056 indicate a 20-fold increase in antibodies targeting pathogenic variants of aSyn, suggesting significant therapeutic potential. The company’s strategic focus on enhancing patient identification and delivering effective, user-friendly treatments aligns well with current trends in Alzheimer’s disease management, positioning AC Immune favorably within a rapidly evolving market.
Bears say
AC Immune SA operates in a high-risk environment typical of the biopharmaceutical industry, characterized by potential clinical readout setbacks and safety concerns. The company is also confronting regulatory uncertainty that may hinder the advancement of its therapeutic and diagnostic products targeting misfolded proteins. Additionally, the increasingly complex and price-sensitive nature of the commercial markets presents further challenges that could negatively impact the profitability and market acceptance of its product candidates.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares